Effect of Loganin (cas 18524-94-2) on experimental diabetic nephropathy
-
Add time:09/07/2019 Source:sciencedirect.com
Connective tissue growth factor (CTGF) plays a pathogenic role in diabetic nephropathy (DN). Loganin (cas 18524-94-2), an iridoid glucoside compound was isolated from Cornus officinalis Sieb. et Zucc. This study was conducted to investigate the efficacy of loganin on DN and to elucidate the potential mechanism. High glucose (HG) stimulated cultured human renal proximal tubular epithelial cells (HK-2) analyzed CTGF expression by Western blotting and investigated whether extracellular signal-regulated kinase (ERK) signaling pathway was involved. Streptozotocin (STZ)-induced experimental DN, randomized to receive intragastric (i.g.) of loganin. Renal tissue, blood and urine samples were collected to determine and analyze. In vitro study, loganin reduced CTGF excretion in HG-induced HK-2 cells through the ERK signaling pathway. In vivo study, I.g. of loganin 5 mg/kg or 10 mg/kg significantly ameliorated renal function and increased body weight. Meanwhile, loganin reduced renal CTGF expression by immunohistochemical staining, reduced serum levels of CTGF. Besides, there were no significant differences in blood sugar levels between the loganin groups compared to the STZ-treated group. Furthermore, loganin ameliorated renal pathology. These results suggested that loganin exerts an early renal protective role to DN. Inhibition of CTGF may be a potential target in DN therapy, which highlights the possibility of using loganin to treat DN.
We also recommend Trading Suppliers and Manufacturers of Loganin (cas 18524-94-2). Pls Click Website Link as below: cas 18524-94-2 suppliers
Prev:Parentucellia latifolia subsp. latifolia: A potential source for Loganin (cas 18524-94-2) iridoids by HPLC-ESI-MSn technique
Next:Endocrine pharmacologyLoganin (cas 18524-94-2) protects against pancreatitis by inhibiting NF-κB activation) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Loganin (cas 18524-94-2) protects against hydrogen peroxide-induced apoptosis by inhibiting phosphorylation of JNK, p38, and ERK 1/2 MAPKs in SH-SY5Y cells09/27/2019
- Hepato-protective effects of Loganin (cas 18524-94-2), iridoid glycoside from Corni Fructus, against hyperglycemia-activated signaling pathway in liver of type 2 diabetic db/db mice09/26/2019
- Loganin (cas 18524-94-2) attenuates diabetic nephropathy in C57BL/6J mice with diabetes induced by streptozotocin and fed with diets containing high level of advanced glycation end products09/25/2019
- Behavioural PharmacologyLoganin (cas 18524-94-2) improves learning and memory impairments induced by scopolamine in mice09/24/2019
- Loganin (cas 18524-94-2) enhances long-term potentiation and recovers scopolamine-induced learning and memory impairments09/10/2019
- Loganin (cas 18524-94-2) possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt/mTOR in experimental models of spinal muscular atrophy09/09/2019
- Endocrine pharmacologyLoganin (cas 18524-94-2) protects against pancreatitis by inhibiting NF-κB activation09/08/2019
- Parentucellia latifolia subsp. latifolia: A potential source for Loganin (cas 18524-94-2) iridoids by HPLC-ESI-MSn technique09/06/2019
- Loganin (cas 18524-94-2) inhibits the inflammatory response in mouse 3T3L1 adipocytes and mouse model☆09/05/2019